Questions About Cancer? 1-800-4-CANCER

Clinical Trial Results

Summaries of Newsworthy Clinical Trial Results

Myeloproliferative Neoplasms Trial Results


Azacitidine Improves Survival in Myelodysplastic Syndromes
(Posted: 03/26/2009) - The DNA methyltransferase inhibitor azacitidine (Vidaza®) improved overall survival in patients with higher-risk myelodysplastic syndromes, according to the March 2009 issue of Lancet Oncology.